Epacadostat
- Generic Name
- Epacadostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT03361228
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 89
- Registration Number
- NCT03358472
- Locations
- 🇺🇸
U of Kansas Cancer Center, Westwood, Kansas, United States
🇦🇺Royal Brisbane & Women s Hospital, Herston, Queensland, Australia
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03348904
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 11
- Registration Number
- NCT03347123
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03342352
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03325465
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 20
- Registration Number
- NCT03322384
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 233
- Registration Number
- NCT03322566
- Locations
- 🇦🇺
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸St. Vincent Healthcare Frontier Cancer Center, Billings, Montana, United States
ðŸ‡ðŸ‡ºOrszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 154
- Registration Number
- NCT03322540
- Locations
- 🇺🇸
Anne Arundel Health System Research Institute, Annapolis, Maryland, United States
🇺🇸Maryland Oncology Hematology, P.A., Rockville, Maryland, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
Epacadostat and Pembrolizumab in Patients With GIST
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1
- Registration Number
- NCT03291054
- Locations
- 🇺🇸
U-M Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.